The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

Also called NCT05566028

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05566028
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05566028. Randomized; double masking; primary purpose treatment. Start 2022-10-12 (actual); primary completion 2024-01-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
Intervention (Drug)
D745 formulation I
Intervention (Drug)
D745 formulation II
Intervention (Drug)
D745 Placebo
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct05566028
Content hash
fc82da21715335383d186ba21f69e9ee534d903e22a49d7f2a1a296337069727